Welcome to our dedicated page for Arcus Bioscience SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arcus Biosciences, Inc. (NYSE: RCUS) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on oncology and inflammatory and autoimmune diseases, Arcus uses SEC filings to report material clinical, financial and corporate events that can be important for investors analyzing RCUS stock.
Form 8‑K current reports frequently highlight significant developments in Arcus’s pipeline and capital structure. For example, 8‑K filings describe the discontinuation of the Phase 3 STAR‑221 trial and the Phase 2 EDGE‑Gastric study after an interim overall survival analysis showed no benefit for the domvanalimab plus zimberelimab and chemotherapy regimen compared with nivolumab plus chemotherapy. Other 8‑Ks detail updated data from the ARC‑20 Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma, including progression-free survival and response metrics, as well as safety findings.
Filings also cover financing and capital markets transactions. One Form 8‑K outlines an underwriting agreement for a public offering of common stock, including the number of shares sold, pricing and net proceeds. Another 8‑K describes a First Amendment to the company’s Loan and Security Agreement with Hercules Capital and other lenders, which restructures remaining term loan commitments into milestone-based tranches tied to Phase 3 data and potential FDA approval, extends the maturity date and adds performance covenants linked to market capitalization, qualified cash levels and potential net product revenue thresholds.
Investors can also use SEC filings to track collaboration and licensing arrangements, such as disclosures related to Arcus’s long-term collaboration with Gilead Sciences and its option and license agreement with Taiho Pharmaceutical. These documents may reference option exercises, milestone structures and rights to co-develop or commercialize investigational medicines like casdatifan, domvanalimab, zimberelimab and quemliclustat in specific territories.
Stock Titan’s interface surfaces these filings alongside AI-powered summaries that explain the practical implications of each document. Instead of parsing detailed legal language alone, readers can review concise explanations of how a loan amendment changes Arcus’s access to capital, what a trial discontinuation means for a particular program, or how a new data disclosure from a Phase 1/1b or Phase 3 study might influence the company’s development strategy. Real-time updates from EDGAR, combined with these AI insights, help users follow Arcus’s quarterly results, material clinical events, financing decisions and collaboration milestones directly from the underlying SEC record.
A trust associated with RCUS stock filed a Rule 144 notice to sell 31,823 shares of Class A common stock through Goldman Sachs & Co. LLC on approximately 01/05/2026. The shares have an aggregate market value of $692,786.71, compared with 122,856,086 shares of this class reported as outstanding. The shares were originally acquired from the issuer in a private transaction on 05/08/2015 for full cash payment. The same trust has sold Class A common stock in prior months, including 44,950 shares on 11/17/2025 for gross proceeds of $913,028.90 and 50,000 shares on 12/04/2025 for $1,230,350.00.
Arcus Biosciences, Inc. Chief Financial Officer reported a sale of company stock in a routine insider transaction. On 12/31/2025, the reporting person sold 6,552 shares of Arcus Biosciences common stock at a price of $23.38 per share. After this transaction, the insider beneficially owned 67,924 shares of common stock in the company.
The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a predetermined schedule, helping separate trading decisions from day-to-day nonpublic information about the business.
Arcus Biosciences, Inc. reported an insider share transfer by its Chief Executive Officer and director. On 12/30/2025, the reporting person transferred 2,400 shares of common stock at a reported price of $0, using transaction code G. After this transaction, the individual directly beneficially owns 2,192,409 shares of Arcus common stock.
According to the notes, the 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, while retaining voting and dispositive power over all of the transferred shares.
Arcus Biosciences Inc. has a notice of proposed sale under Rule 144 for 6,552 shares of common stock, to be sold through Merrill Lynch on the NYSE around 12/31/2025, with an aggregate market value of $153,185.76. Common shares outstanding were 107,973,536.
The seller, Robert C. Goeltz II, acquired these 6,552 shares on 12/15/2025 as a restricted stock unit grant from Arcus Biosciences, recorded as equity compensation. Over the prior three months, he reported multiple sales of common stock: 5,000 shares on 10/28/2025 for $100,000, 5,000 shares on 11/26/2025 for $125,000, 6,702 shares on 12/16/2025 for $146,668.58, and 5,960 shares on 12/17/2025 for $132,070.62.
Arcus Biosciences, Inc. reported that its general counsel sold company stock in mid-December 2025 in transactions related to restricted stock unit (RSU) vesting. On December 16, 2025, 7,658 shares of common stock were sold at a weighted average price of $21.8843, leaving 131,544 shares beneficially owned afterward. On December 17, 2025, a further 6,810 shares were sold at a weighted average price of $22.1595, resulting in 124,734 shares beneficially owned. The filing explains that these sales were made by the issuer on the reporting person’s behalf to cover tax withholding obligations triggered by RSU vesting under an equity administration policy implemented on May 22, 2025, and are described as non‑discretionary trades. The remaining holdings include one share acquired through the company’s employee stock purchase plan and the unvested portion of the reporting person’s RSU grants.
Arcus Biosciences Chief Medical Officer reports automatic share sales and corrects equity award vesting terms. On 12/16/2025 and 12/17/2025, the CMO sold 5,052 and 4,494 shares of common stock, respectively, as reported sales to cover tax withholding obligations tied to vesting restricted stock units. The filing states these sales occurred automatically under the company’s equity administration policy and were not discretionary trades. After these transactions, the CMO beneficially owned 70,141 and then 65,647 shares, including unvested RSUs. The document also corrects the vesting schedule for awards granted on February 10, 2025: RSUs vest in four equal annual installments beginning December 15, 2025, and stock options become exercisable in 48 equal monthly installments after January 31, 2025, subject to continued service.
Arcus Biosciences’ Chief Accounting Officer reported routine stock sales over three days in December 2025. On December 16, 17, and 18, 2025, the officer reported selling 2,376, 2,113, and 4,343 shares of common stock, respectively, at weighted average prices of $21.8843, $22.1595, and $22.2458 per share.
According to the footnotes, the first two sales were made by the issuer on the officer’s behalf to cover tax withholding obligations from vesting restricted stock units and occurred automatically under the company’s equity administration policy implemented on May 22, 2025. The sales on December 18, 2025 were effected under a Rule 10b5-1 trading plan adopted on June 6, 2025. After these transactions, the officer beneficially owned 18,531 shares, including unvested RSUs.
Arcus Biosciences, Inc. reported insider share sales by its Chief Financial Officer related to restricted stock unit (RSU) vesting. On 12/16/2025, the CFO sold 6,702 shares of common stock at a weighted average price of $21.8843 per share, and on 12/17/2025, sold an additional 5,960 shares at a weighted average price of $22.1595 per share.
The company states these shares were sold by the issuer on the CFO’s behalf to cover tax withholding obligations arising from the vesting of previously granted RSUs, under an equity administration policy implemented on May 22, 2025, and that the sales were not discretionary trades. Following these transactions, the CFO beneficially owned 80,436 shares after the first sale and 74,476 shares after the second sale, which include the unvested portion of her RSU grants.
Arcus Biosciences, Inc. reported that its Chief Operating Officer, a company officer, sold shares of common stock in mid-December 2025 in connection with restricted stock unit (RSU) vesting. On 12/16/2025, 11,225 shares were sold at a weighted average price of $21.8843, leaving 203,007 shares beneficially owned. On 12/17/2025, 9,983 shares were sold at a weighted average price of $22.1595, leaving 193,024 shares beneficially owned.
The filing explains that these sales were made by the issuer on the officer’s behalf solely to cover tax withholding obligations tied to the vesting of previously granted RSUs, and occurred automatically under the company’s equity administration policy rather than as discretionary trades. The remaining beneficial ownership figure includes unvested portions of the officer’s RSU grants.
Arcus Biosciences’ president reports automatic tax‑related share sales tied to RSU vesting. On 12/16/2025 and 12/17/2025, the reporting officer sold 11,225 and 9,983 shares of Arcus Biosciences common stock, respectively, at weighted average prices of $21.8843 and $22.1595 per share. The filing explains these sales were made by the company on the officer’s behalf to cover tax withholding obligations when certain previously granted restricted stock units vested, under an equity administration policy implemented on May 22, 2025, and were not discretionary trades. After these transactions, the officer beneficially owns 346,012 shares directly, including unvested RSUs, and 954,063 shares indirectly through a trust.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
